<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03199586</url>
  </required_header>
  <id_info>
    <org_study_id>NP-G2-044-P1-01</org_study_id>
    <nct_id>NCT03199586</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies</brief_title>
  <official_title>First-in-Human, Dose Finding, Open Label Phase 1A-1B Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novita Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translational Drug Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novita Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on&#xD;
      a daily X 28 days followed by a 14 day rest period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Actual">May 7, 2020</completion_date>
  <primary_completion_date type="Actual">May 7, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Establish the safe recommended phase 2 dose</measure>
    <time_frame>24 months</time_frame>
    <description>Treatment related adverse events assessed by CTCAE V4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify and characterize preliminary anti tumor activity</measure>
    <time_frame>24 months</time_frame>
    <description>Anti tumor activity assessed using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacokinetics of NP-G2-044</measure>
    <time_frame>24 months</time_frame>
    <description>Drug exposure assessed by area under the curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>24 months</time_frame>
    <description>Time to peak plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>24 months</time_frame>
    <description>Peak plasma concentration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Pancreas Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Esophagus Cancer</condition>
  <condition>Liver Cancer</condition>
  <condition>Ovary Cancer</condition>
  <condition>Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies</condition>
  <arm_group>
    <arm_group_label>NP-G2-044</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NP-G2-044</intervention_name>
    <description>capsule</description>
    <arm_group_label>NP-G2-044</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent and mental capability to understand the informed consent&#xD;
&#xD;
          2. Male or female patients &gt; 18 years of age&#xD;
&#xD;
          3. Histologically or cytologically documented locally advanced or metastatic solid tumor&#xD;
             malignancies either treatment-refractory or otherwise ineligible for treatment with&#xD;
             standard-of-care agents/regimens&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1&#xD;
&#xD;
          5. Evaluable or measurable disease per RECIST v1.1&#xD;
&#xD;
          6. Life expectancy &gt; 3 months&#xD;
&#xD;
          7. ECG without evidence of clinically meaningful conduction abnormalities or active&#xD;
             ischemia as determined by the Investigator&#xD;
&#xD;
          8. Acceptable organ and marrow function as defined below:&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1,500 cells/μL&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               -  Platelets &gt; 100,000 cells/μL&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
               -  Albumin ≥ 3 g/dL&#xD;
&#xD;
               -  Aspartate aminotransferase (AST)/alanine transaminase (ALT)/alkaline phosphatase&#xD;
                  (ALP)/Gamm-glutamyl transferase (GGT) ≤ 2.5 times ULN. For Phase 1A only, if&#xD;
                  liver metastases are present, AST/ALT/ALP &lt; 5 times ULN&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 mg./dL and a measured creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
               -  Prothrombin time (PT)/partial thromboplastin time (PTT) ≤ 1.5 times ULN&#xD;
&#xD;
          9. Women of child-bearing potential (defined as a female who has experienced menarche and&#xD;
             who has not undergone successful surgical sterilization (hysterectomy, bilateral&#xD;
             salpingectomy, or bilateral oophorectomy) or is not postmenopausal (defined as&#xD;
             amenorrhea for at least 12 consecutive months with an appropriate clinical profile at&#xD;
             the appropriate age, e.g., greater than 45 years) must have a negative serum pregnancy&#xD;
             test prior to first dose of study drug.&#xD;
&#xD;
         10. Male and female patients with reproductive potential must agree to use adequate&#xD;
             contraceptive precautions throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chemotherapy, radiotherapy or other anti-cancer treatment within 4 weeks or 5&#xD;
             half-lives (whichever is shorter) (6 weeks for nitrosoureas or mitomycin C) of the&#xD;
             first dose of study drug or patients who in opinion of Investigator have not recovered&#xD;
             from AEs due to agents administered greater than 4 weeks earlier (prior immunotherapy&#xD;
             is allowed)&#xD;
&#xD;
          2. Participation in any other clinical investigation using an experimental drug within 4&#xD;
             weeks of first dose of study drug&#xD;
&#xD;
          3. Failure to recover to ≤ grade 1 toxicity (except grade 1-2 alopecia or neuropathy)&#xD;
             associated with previous chemotherapy, radiotherapy, biologic, hormone or prior&#xD;
             investigational therapy&#xD;
&#xD;
          4. Known untreated brain metastases or treated brain metastases that have not been&#xD;
             radiographically and clinically stable (i.e. not requiring steroids) ≥ 4 weeks prior&#xD;
             to study enrollment&#xD;
&#xD;
          5. Baseline prolongation of QT/QTc interval (QTc interval &gt; 470 msec in women and &gt;450&#xD;
             msec in men)&#xD;
&#xD;
          6. Uncontrolled intercurrent illness (including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations) that in opinion of Investigator&#xD;
             would limit compliance with study requirements&#xD;
&#xD;
          7. Women who are pregnant or breastfeeding&#xD;
&#xD;
          8. Prior allogenic hematopoietic stem cell transplant or allogenic bone marrow transplant&#xD;
             or prior solid organ transplant or current use of immuno suppression drugs or&#xD;
             anti-transplant rejection drugs&#xD;
&#xD;
          9. Prior history of clinically significant gastrointestinal bleeding, intestinal&#xD;
             obstruction or gastrointestinal perforation within 6 months of study enrollment&#xD;
&#xD;
         10. Sponsor reserves right to exclude any patient from the study on basis of pre-study&#xD;
             medical histories, physical examination findings, clinical laboratory results, prior&#xD;
             medications, or other entrance criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jillian Zhang, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Novita Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced or metastatic treatment-refractory solid tumor malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

